Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Filgotinib induction and maintenance study in moderately to severely active ulcerative colitis
NL-OMON47588Phase 2Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of filgotinib in autoimmune colitis (5 arms), sponsored by Gilead Sciences. Primary endpoint: Primary efficacy endpoint. Started Jul 2018; status: active, not recruiting.
02
Drugs
filgotinib
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON47588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47588.